Arrowhead Pharmaceuticals (GB:0HI3)

Arrowhead Pharmaceuticals (0HI3) Income Statement


Arrowhead Pharmaceuticals Income Statement

Last quarter (Q2 2024), Arrowhead Pharmaceuticals's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q2, Arrowhead Pharmaceuticals's net income was $-125.30M. See Arrowhead Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
$ 35.47M$ 240.74M$ 243.23M$ 138.29M$ 87.99M$ 168.80M
Cost of Revenue
Gross Profit
$ 35.47M$ 240.74M$ 243.23M$ 138.29M--
Operating Expense
$ 509.24M$ 445.74M$ -421.74M$ -287.32M$ 181.15M$ 107.60M
Operating Income
$ -473.77M$ -205.00M$ -178.51M$ -149.04M$ -93.16M$ 61.19M
Net Non Operating Interest Income Expense
$ -25.71M$ -18.33M$ 5.03M$ 6.12M$ 9.19M$ 6.96M
Other Income Expense
$ -21.42M$ -16.84M$ -765.00K$ -2.07M$ -583.00K-
Pretax Income
$ -478.06M$ -206.49M$ -172.71M$ -140.85M$ -84.55M$ 68.15M
Tax Provision
$ -533.00K$ 2.78M$ 3.79M$ 2.00K$ 2.00K$ 173.55K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -470.79M$ -205.28M$ -176.06M$ -140.85M$ -84.55M$ 67.97M
Basic EPS
$ -4.24$ -1.92$ -1.67$ -1.36$ -0.84$ 0.72
Diluted EPS
$ -4.26$ -1.92$ -1.67$ -1.36$ -0.84$ 0.69
Basic Average Shares
$ 444.90M$ 106.75M$ 105.43M$ 103.75M$ 100.72M$ 93.86M
Diluted Average Shares
$ 443.52M$ 106.75M$ 105.43M$ 103.75M$ 100.72M$ 98.61M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 509.24M$ 445.74M$ -421.74M$ -287.32M$ 181.15M$ 107.60M
Net Income From Continuing And Discontinued Operation
$ -470.79M$ -205.28M$ -176.06M$ -140.85M$ -84.55M$ 67.97M
Normalized Income
$ -435.49M$ -163.13M--$ -84.55M$ 67.97M
Interest Expense
$ -452.18M$ -188.16M$ -172.71M$ -140.85M$ -93.16M$ 61.19M
$ -436.25M$ -175.67M$ -162.29M$ -132.58M$ -87.22M$ 65.63M
Currency in USD

Arrowhead Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis